<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154722</url>
  </required_header>
  <id_info>
    <org_study_id>0980419HRPED</org_study_id>
    <nct_id>NCT04154722</nct_id>
  </id_info>
  <brief_title>Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children</brief_title>
  <acronym>[XDRTYPHOID]</acronym>
  <official_title>Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziauddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziauddin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether XDR Typhoid fever in children can be effectively treated with&#xD;
      monotherapy (meropenum alone), or a combination (meropenum and azithromycin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complicated XDR Enteric fever is a very serious systemic disease, caused by an extremely&#xD;
      resistant mutant strain of Salmonella Typhi ( the H58 S. Typhi superbug,) that as the name&#xD;
      suggests is resistant to not only the first but also the second tier drugs conventionally&#xD;
      used for treatment of the same. And as such, warrants immediate antibiotic therapy, but in&#xD;
      view of the extended antimicrobial resistance the treatment options are limited to only two&#xD;
      effective drugs viz Carbepenem and Azithromycin, as per culture sensitivity.&#xD;
&#xD;
      So far, in the absence of universal standardized treatment protocols for XDR complicated&#xD;
      typhoid fever in children, random use of either one or both in combination is the current&#xD;
      practice.&#xD;
&#xD;
      However, keeping antibiotic stewardship in mind, it is imperative to ascertain whether&#xD;
      meropenum alone is effective or should be combined with azithromycin in the treatment of this&#xD;
      serious disease.&#xD;
&#xD;
      Our study therefore compares the efficacy of monotherapy with meropenum or combination with&#xD;
      azithromycin based on clinical and microbiologic remission, shortened hospital stay and less&#xD;
      chances of relapse in order to then formulate a standardized protocol to treat complicated&#xD;
      XDR typhoid in children thus preventing yet further antimicrobial resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical clearance</measure>
    <time_frame>10 days</time_frame>
    <description>improvement of the signs and symptoms as given in the operational definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bacterial clearance</measure>
    <time_frame>5 days</time_frame>
    <description>negative blood cultures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>relapse of typhoid fever</measure>
    <time_frame>15 days after completing treatment</time_frame>
    <description>reappearance of the signs and symptoms of typhoid fever along with positive blood cultures</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>meropenum and azithromycin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenum group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>inj meropenum 20mg/kg/dose I/v in 3 divided doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem Injection</intervention_name>
    <description>inj meropenum for 10 days</description>
    <arm_group_label>meropenum and azithromycin group</arm_group_label>
    <arm_group_label>meropenum group</arm_group_label>
    <other_name>meroneum</other_name>
    <other_name>penro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin Powder</intervention_name>
    <description>syp azithromycin for10days</description>
    <arm_group_label>meropenum and azithromycin group</arm_group_label>
    <other_name>azomax</other_name>
    <other_name>zetro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with extended drug resistant typhoid fever defined as culture proven typhoid fever&#xD;
        caused by Salmonella Typhi or Para typhi resistant to Ampicillin, Chloramphenicol,Co&#xD;
        trimoxazole,Quinolones and Ceftriaxone along with two or more of the following condition&#xD;
&#xD;
          -  High grade fever spikes for more than three days&#xD;
&#xD;
          -  Refusal to eat or drink&#xD;
&#xD;
          -  Drowsy or Unconscious&#xD;
&#xD;
          -  Convulsions&#xD;
&#xD;
          -  Dehydration due to diarrhea or vomiting&#xD;
&#xD;
          -  Abdominal distension with or without tenderness&#xD;
&#xD;
          -  Bleeding diathesis like petechial rash, gum bleed, melena&#xD;
&#xD;
          -  Jaundice or alanine transaminase more than twice of the normal range&#xD;
&#xD;
          -  Thrombocytopenia less than fifty thousand&#xD;
&#xD;
          -  Increase Prothrombin time and activated partial thromboplastin time&#xD;
&#xD;
          -  Electrolyte imbalance like hyponatremia, hypernatremia, hypokalemia, hyperkalemia,&#xD;
             metabolic acidosis&#xD;
&#xD;
          -  Hypoglycemia&#xD;
&#xD;
          -  Signs of shock like cold and mottled skin, feeble pulses, tachycardia, decreased blood&#xD;
             pressure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not given informed consent&#xD;
&#xD;
          -  Children who need ventilator or two inotrope support&#xD;
&#xD;
          -  Severe malnutrition/immunocompromised patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>farhana zafar, mbbs,fcps</last_name>
    <role>Principal Investigator</role>
    <affiliation>ziauddin university north campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziauddin University</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziauddin University</investigator_affiliation>
    <investigator_full_name>Dr. Fatima G Siddiqi</investigator_full_name>
    <investigator_title>MD resident</investigator_title>
  </responsible_party>
  <keyword>XDR TYPHOID FEVER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

